Kairos Pharma Ltd (AMEX: KAPA) kicked off on Friday, up 12.77% from the previous trading day, before settling in for the closing price of $0.94. Over the past 52 weeks, KAPA has traded in a range of $0.85-$4.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -222.58%. With a float of $5.82 million, this company’s outstanding shares have now reached $12.85 million.
In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Kairos Pharma Ltd (KAPA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Kairos Pharma Ltd is 57.51%, while institutional ownership is 2.97%. The most recent insider transaction that took place on Nov 25 ’24, was worth 318. In this transaction VP of Research and Development of this company bought 200 shares at a rate of $1.59, taking the stock ownership to the 133,057 shares. Before that another transaction happened on Nov 22 ’24, when Company’s Chief Financial Officer bought 2,500 for $1.50, making the entire transaction worth $3,750. This insider now owns 60,796 shares in total.
Kairos Pharma Ltd (KAPA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -222.58% per share during the next fiscal year.
Kairos Pharma Ltd (AMEX: KAPA) Trading Performance Indicators
Take a look at Kairos Pharma Ltd’s (KAPA) current performance indicators. Last quarter, stock had a quick ratio of 2.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.44 in one year’s time.
Technical Analysis of Kairos Pharma Ltd (KAPA)
Analysing the last 5-days average volume posted by the [Kairos Pharma Ltd, KAPA], we can find that recorded value of 0.2 million was lower than the volume posted last year of 2.25 million. As of the previous 9 days, the stock’s Stochastic %D was 26.07%. Additionally, its Average True Range was 0.14.
During the past 100 days, Kairos Pharma Ltd’s (KAPA) raw stochastic average was set at 8.73%, which indicates a significant decrease from 50.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.79% in the past 14 days, which was lower than the 195.24% volatility it showed in the past 100 days.
Now, the first resistance to watch is $1.2133. This is followed by the second major resistance level at $1.3667. The third major resistance level sits at $1.4833. If the price goes on to break the first support level at $0.9433, it is likely to go to the next support level at $0.8267. Now, if the price goes above the second support level, the third support stands at $0.6733.
Kairos Pharma Ltd (AMEX: KAPA) Key Stats
The company with the Market Capitalisation of 14.52 million has total of 13,700K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -1,812 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -1,047 K.
